BIIB vs VCYT: fair value comparison
Biogen Inc. and Veracyte, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, BIIB currently sits closer to the top of our discount ranking. VCYT carries the stronger quality grade.
| BIIB | VCYT | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $218.50 | $44.85 |
| 12-month range | $139.63–$202.95 | $30.11–$59.85 |
| Sector rank | #83 of 113 Healthcare | #85 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | A | — |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: BIIB fair value analysis · VCYT fair value analysis